DURECT Corp logo

DRRX

DURECT Corp

$0.46

Earnings Summary

Revenue
$4.57Mn
Net Profits
$-8.11Mn
Net Profit Margins
-177.67%

Highlights

Revenue:

DURECT Corp’s revenue jumped 26.58% since last year same period to $4.57Mn in the Q1 2017. On a quarterly growth basis, DURECT Corp has generated 29.85% jump in its revenue since last 3-months.

Net Profits:

DURECT Corp’s net profit fell -3.34% since last year same period to $-8.11Mn in the Q1 2017. On a quarterly growth basis, DURECT Corp has generated 7.91% jump in its net profits since last 3-months.

Net Profit Margins:

DURECT Corp’s net profit margin jumped 18.36% since last year same period to -177.67% in the Q1 2017. On a quarterly growth basis, DURECT Corp has generated 29.08% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the DURECT Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.05
EPS Estimate Current Year
-0.05

Highlights

EPS Estimate Current Quarter:

DURECT Corp’s earning per share (EPS) estimates for the current quarter stand at -0.05 - a 6.6% jump from last quarter’s estimates.

EPS Estimate Current Year:

DURECT Corp’s earning per share (EPS) estimates for the current year stand at -0.05.

Key Ratios

Key ratios of the DURECT Corp post its Q2 2022 earnings

Earning Per Share (EPS)
-0.05
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.64

Highlights

Earning Per Share (EPS):

DURECT Corp’s earning per share (EPS) fell -24.38% since last year same period to -0.05 in the Q2 2022. This indicates that the DURECT Corp has generated -24.38% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. DURECT Corp’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. DURECT Corp’s return on equity (ROE) stands at -0.64.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-05
-0.05
-0.05
-7.07%
2022-05-05
-0.05
-0.05
6.19%

Company Information

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.

Organisation
DURECT Corp
Headquarters
10260 Bubb Road, Cupertino, CA, United States, 95014-4166
Employees
79
Industry
Health Technology
CEO
James Brown

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*